ClinicalTrials.gg
RecruitingNCT07415954Updated Sep 11, 2026

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

A Phase 2 interventional study of NNC0662-0419 and Semaglutide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Recruiting at 63 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 25 open to participants now, 29 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.

Planned enrollment
188th of 428
270 · median 209
Started
2026
with 22 others
Phase 2
37 of 643
2 open now
Primary completion
2027-09
later than 8 of 28 live
Registered
626th of 643
by date

Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 188th largest by planned enrollment of the 428 interventional ones that give a count, is one of 23 that started in 2026, is one of 37 in phase 2, reaches primary completion later than 8 of the 28 other live ones, and was the 626th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

25 of the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex at birth).
  • Age 18-75 years (both inclusive) at the time of signing the .
  • (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole [mmol/mol]) (both inclusive) as assessed by central laboratory at screening.
  • Willingness to obtain a high weight loss (greater than [>] 25% of weight at baseline).

Exclusion criteria

Exclusion criteria

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    NNC0662-0419

    Participants will receive NNC0662-0419 subcutaneously (s.c.) in a dose escalating manner once weekly.

    Drug: NNC0662-0419

  • Active comparator
    Semaglutide

    Participants will receive semaglutide s.c. once weekly.

    Drug: Semaglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to their respective investigational medicinal product s.c. once weekly.

    Drug: Placebo

Interventions

  • NNC0662-0419 will be administered subcutaneously.

  • Semaglutide will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Change in glycated haemoglobin (HbA1c) (week 16)

    Measured as percentage-point (%-point).

    Time frame: From baseline (week 0) to week 16

  2. Change in HbA1c (week 28)

    Measured as %-point.

    Time frame: From baseline (week 0) to week 28

  3. Change in HbA1c (week 40)

    Measured as %-point.

    Time frame: From baseline (week 0) to week 40

Secondary outcomes

  1. Relative change in body weight

    Measured as percentage (%).

    Time frame: From baseline (week 0) to (week 40)

  2. Change in body weight

    Measured as kilogram (kg).

    Time frame: From baseline (week 0) to (week 40)

  3. Change in HbA1c

    Measured as %-point.

    Time frame: From baseline (week 0) to (week 16, 28 and 40)

  4. Change in Fasting Plasma Glucose (FPG)

    Measured as millimoles per litre (mmol/L).

    Time frame: From baseline (week 0) to (week 16, 28 and 40)

  5. Change in Body Mass Index (BMI)

    Measured in kilograms per square metre (kg/m\^2).

    Time frame: From baseline (week 0) to (week 40)

  6. Change in waist circumference

    Measured in centimetre (cm).

    Time frame: From baseline (week 0) to (week 40)

  7. Change in high sensitivity C-Reactive Protein (hsCRP)

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 40)

  8. Change in total cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 40)

  9. Change in High-Density Lipoprotein (HDL) cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 40)

  10. Change in Low-Density Lipoprotein (LDL) cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 40)

  11. Change in triglycerides

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 40)

  12. Change in Urine Albumin Creatinine Ratio (UACR)

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 16, 28 and 40)

  13. Change in estimated Glomerular Filtration Rate (eGFR) (creatinine cystatin C-based Chronic Kidney Disease-Epidemiology Collaboration [CKD-EPI] 2021)

    Measured in millilitres per minute per 1.73 square metre (mL/min/1.73 m\^2).

    Time frame: From baseline (week 0) to (week 40)

  14. Number of adverse events

    Measured as number of events.

    Time frame: From baseline (week 0) to (week 48)

07

Study locations

50 of 63 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 16 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 17, 2026
StartActual
Apr 17, 2026
Primary completionEst.
Sep 3, 2027
CompletionEst.
Oct 1, 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07415954
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Apr 17, 2026
Primary completion
Sep 3, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0662-0419

Start the discussion